New Zealand markets closed

NVS Jan 2025 72.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
17.450.00 (0.00%)
As of 12:03PM EDT. Market open.
Full screen
Previous close17.45
Open17.45
Bid26.20
Ask30.80
Strike72.50
Expiry date2025-01-17
Day's range17.45 - 17.45
Contract rangeN/A
Volume2
Open interest7
  • Zacks

    Novartis (NVS) to Report Q1 Earnings: What to Expect?

    Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.

  • Reuters

    US FDA mandates label updates on CAR-T cancer therapies

    The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the serious risk of T-cell blood cancer in patients who use these therapies. The health regulor has required related updates to other sections of the label such as warnings and precautions, postmarketing experience, patient counseling information and medication guide. In January, the FDA asked a host of drugmakers including Gilead Sciences, Johnson & Johnson and Novartis to add a boxed warning to their CAR-T cancer therapies, as it received reports of patients developing a type of T-cell blood cancer after being treated with them.

  • Zacks

    Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS

    Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.